mTOR

Inhibitory Selectivity
Catalog No.Inhibitor Name mTOR mTORC1 mTORC2 Other Targets
A10133Dactolisib
***
p110α,p110γ,p110δ
A10782Rapamycin
****
A10374Everolimus
***
A10114AZD8055
****
DNA-PK,PI3Kδ,PI3Kα
A10906Temsirolimus
*
A10726PI-103
*
p110α,p110δ,p110β
A10505KU-0063794
**
**
A10746Torkinib
**
p110δ,PDGFR,DNA-PK
A10295Ridaforolimus
****
A11461INK 128
****
PI3Kα,PI3Kγ,PI3Kδ
A10997Voxtalisib Analogue
*
PI3Kγ,PI3Kα,PI3Kδ
A11587Torin 1
***
***
**
DNA-PK,p110γ,C2α
A11035Omipalisib
****
****
p110α,p110δ,p110γ
A11056OSI-027
***
*
*
PI3Kγ,DNA-PK,PI3Kα
A11024PF-04691502
**
PI3Kδ,PI3Kα,PI3Kγ
A11023Apitolisib
*
p110α,p110δ,p110γ
A10438GSK1059615
**
PI3Kα,PI3Kβ,PI3Kδ
A11079Gedatolisib
****
PI3Kα,PI3Kγ
A10989WYE-354
***
PI3Kα,PI3Kγ
A11303Vistusertib
***
P-Akt (S473),pS6 (S235/236)
A11586Torin 2
****
ATM,ATR,DNA-PK
A11038WYE-125132
****
A11207PP121
**
PDGFR,Hck,VEGFR
A11187WYE-687
***
PI3Kα,PI3Kγ,p38α
A11169CH5132799
*
PI3Kα,PI3Kγ,PI3Kβ
A11188WAY-600
**
PI3Kα,PI3Kγ
A13328ETP-46464
****
ATR,DNA-PK,PI3Kα
A11443GDC-0349
***
PI3Kα
A12395XL388
**
**
*
CYP2C9,CYP3A4
A13078CC-223
**
cFMS,FLT4,DNA-PK
A16276Voxtalisib
*
PI3Kγ,PI3Kα,PI3Kδ
A11950Zotarolimus
***
A10389Tacrolimus
A11162BGT226
PI3Kα,PI3Kγ,PI3Kβ
A10693Palomid 529
A10210Chrysophanic Acid
EGFR
A11537QL-IX-55
A12480VS-5584
****
PI3Kα, PI3Kδ, PI3Kγ, PI3Kβ
A12704SF1126
PI3K
A12935PF-04979064
****
PI3Kα, PI3Kδ, PI3Kγ, PI3Kβ, Akt
A14432GNE-493
***
PI3Kα, PI3Kδ, PI3Kγ, PI3Kβ
A15175mTOR inhibitor (mTOR-IN-1)
***
A15508MHY1485
A16126LY3023414
PI3Kα, Akt1, DNA-PK

Notes:
1.Hover mouse over " * " to view the IC50 value.(A few compounds have proven potency but without published IC50 data.)
2.For more details about the compound, click on the product name of your interest.
3.The higher the number of " * " is, the more potent the inhibitor or activator is.
4."" refers to compounds which do inhibitory effects on the related isoform, but without specific value.



Items 1 to 25 of 44 total

per page
Page:
  1. 1
  2. 2

Set Descending Direction
Catalog No. Product Name Application Product Information
A11303 SALE

AZD2014 (Vistusertib)

mTORC1/2 inhibitor
AZD2014 is an orally bioavailable inhibitor of the mammalian target of rapamycin (mTOR) with potential antineoplastic activity. mTOR kinase inhibitor.
A10114 SALE

AZD8055

mTOR Inhibitor
AZD8055 is a potent, selective, and orally bioavailable ATP-competitive mTOR kinase inhibitor with an IC50 of 0.8 nM.
A10133 SALE

BEZ235 (NVP-BEZ235, Dactolisib)

PI3K/mTOR Inhibitor
BEZ235 (NVP-BEZ235) inhibits PI3K and mTOR kinase activity by binding to the ATP-binding cleft of these enzymes.
A15779

CC-115

mTOR/DNA-PK inhibitor
CC-115 is a inhibitor of mTOR/DNA-PK (IC50= 21/ 13 nM).
A13078

CC-223

mTOR Inhibitor
CC-223 is a potent mTOR kinase inhibitor (IC50=16 nM), with >150-fold sensitivity over the related lipid kinase PI3K-alpha (IC50=4uM).
A11169 SALE

CH5132799

PI3K inhibitor

CH5132799 is a novel class I PI3K inhibitor, which exhibited a strong inhibitory activity especially against PI3Kα (IC(50)=0.014 μM).

A10295

Deforolimus (Ridaforolimus)

mTOR Inhibitor

Deforolimus (Ridaforolimus) is an investigational targeted and small-molecule inhibitor of the protein mTOR. Blocking mTOR creates a starvation-like effect in cancer cells by interfering with cell growth, division, metabolism, and angiogenesis.

A13328

ETP-46464

ATR inhibitor
ETP-46464 is a potent and selective inhibitor of ATR with IC50 of 25 nM.
A10374 SALE

Everolimus (RAD001)

mTOR inhibitor
Everolimus (RAD-001) is the 40-O-(2-hydroxyethyl) derivative of sirolimus and works similarly to sirolimus as an mTOR inhibitor.
A10389 SALE

FK-506

mTOR inhibitor
FK-506 is an immunosuppressive drug that is mainly used after allogeneic organ transplant to reduce the activity of the patient's immune system and so lower the risk of organ rejection. It reduces interleukin-2 (IL-2) production by T-cells.
A11443 SALE

GDC-0349

mTOR inhibitor
GDC-0349 is under evaluating the Safety and Tolerability in Patients with locally advanced or metastatic solid tumors or non hodgkin's lymphoma.
A11023 SALE

GDC-0980 (Apitolisib, RG7422)

mTOR/PI3K Inhibitor
GDC-0980 (RG7422) is a selective, potent, orally bioavailable inhibitor of Class I PI3 kinase and mTOR kinase (TORC1/2) with in vitro IC50 of 5, 27, 7 and 14 nM for p110 α, β, δ and γ isoforms, respectively.
A14432

GNE-493

Dual Pan PI3k/mTOR inhibitor
GNE-493 is potent, selective, and orally available pan-PI3-kinase and dual pan-PI3-kinase/mTOR inhibitor with potential anticancer activity.
A10438 SALE

GSK1059615

mTOR/PI3K Inhibitor
GSK1059615 is a potent, reversible, ATP-competitive, thiazolidinedione inhibitor of PI3Kα (IC50 = 2 nM).
A11035 SALE

GSK2126458 (Omipalisib)

mTOR/PI3K Inhibitor,
GSK2126458 is a highly potent, orally bioavailable inhibitor of PI3Kα and mTOR with in vivo activity in both pharmacodynamic and tumor growth efficacy models.
A11461 SALE

INK 128 (MLN0128)

mTOR inhibitor
INK 128 is a TORC1/2 inhibitor, is also an orally bioavailable inhibitor of raptor-mTOR (TOR complex 1 or TORC1) and rictor-mTOR (TOR complex 2 or TORC2) with potential antineoplastic activity.
A10505 SALE

KU-0063794

mTOR Inhibitor
KU-0063794 is a selective inhibitor of mammalian target of rapamycin (mTOR) (IC50 ~10 nM for mTORC1 and mTORC2 respectively).
A15147

LY 303511

PI3K inhibitor
LY303511, an inactive analogue of LY294002, is a mTOR inhibitor that did not inhibit PI3-K.
A16126

LY3023414

PI3K/mTOR Dual Inhibitor
LY3023414 is an oral ATP competitive inhibitor of the class I PI3K isoforms, mTOR and DNA-PK, extracted from patent WO/2012097039A1, compound example 1, has an IC50 of 64.9 nM, 42.1 nM, 10.6 nM, 19.1 nM for Akt1(pT308), Akt1 (pS473), P70S6(pT389), S6RP(pS240/242).
A15508 SALE

MHY1485

mTOR inhibitor
MHY1485 is a mTOR activator; inhibits the autophagic process by inhibition of fusion between autophagosomes and lysosomes leading to the accumulation of LC3II protein and enlarged autophagosomes.
A15175

mTOR inhibitor (mTOR-IN-1)

mTOR inhibitor
mTOR inhibitor is a potent and selective ATP-competitive inhibitor of mTOR with Ki of 1.5 nM.
A11162 SALE

NVP-BGT226

PI3K inhibitor

NVP-BGT226, novel phosphoinositide 3-kinase/mTOR dual inhibitor, displays potent growth-inhibitory activity against human head and neck cancer cells in vitro and in vivo.

A11056

OSI-027

mTOR inhibitor
OSI-027 is a potent, selective and orally bioavailable mTOR kinase inhibitor that inhibits the kinase activity associated with both the TORC1 and TORC2 complexes of mTOR.
A10693 SALE

Palomid 529 (P529)

AKT Inhibitor
Palomid 529 is a dual TORC1/2 inhibitor of the PI3K/Akt/mTOR pathway having broad activity in angiogenesis and cellular proliferation.
A11024 SALE

PF-04691502

PI3K/mTOR Inhibitor
PF-04691502 is a PI3K/mTOR kinase inhibitor, is also an agent targeting the phosphatidylinositol 3 kinase (PI3K) and mammalian target of rapamycin (mTOR) in the PI3K/mTOR signaling pathway.

Items 1 to 25 of 44 total

per page
Page:
  1. 1
  2. 2

Set Descending Direction